Intelligence Feed event · Policy · 2026-08-27

    FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic Cancer

    Question

    FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic Cancer

    Direct answer

    The US FDA granted marketing approval for Revolution Medicines' lead therapeutic RASONQUE (daraxonrasib), making it the first broad RAS-targeted medicine authorized for metastatic pancreatic adenocarcinoma in pretreated patients or those ineligible for multiagent chemotherapy. The approval was supported by data from the Phase 3 RASolute 302 trial. Specialty pharmacy distributor Onco360 has been mobilized for nationwide commercial distribution.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-27
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic Cancer”, revision 1, evidence through 2026-08-27. https://marketontology.com/market-events/2026-08-27/fda-approves-revolution-medicines-rasonque-for-metastatic-pancreatic-cancer-2ebe68

    POLICY
    FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic Cancer
    The US FDA granted marketing approval for Revolution Medicines' lead therapeutic RASONQUE (daraxonrasib), making it the first broad RAS-targeted medicine authorized for metastatic pancreatic adenocarcinoma in pretreated patients or those ineligible for multiagent chemotherapy. The approval was supported by data from the Phase 3 RASolute 302 trial. Specialty pharmacy distributor Onco360 has been mobilized for nationwide commercial distribution.
    RVMD
    Impact
    75
    AUG 27
    SIG
    92%
    RVMD
    FDA Approves Revolution Medicines' RASONQUE for Metastatic Pancreatic Cancer
    The US FDA granted marketing approval for Revolution Medicines' lead therapeutic RASONQUE (daraxonrasib), making it the first broad RAS-targeted medicine authorized for metastatic pancreatic adenocarcinoma in pretreated patients or those ineligible for multiagent chemotherapy. The approval was supported by data from the Phase 3 RASolute 302 trial. Specialty pharmacy distributor Onco360 has been mobilized for nationwide commercial distribution.
    → Commercial regulatory approval unlocks direct product revenue in oncology markets, transitioning clinical pipeline assets to commercial pharmaceutical cash flows.
    Impact
    The US FDA granted marketing approval for Revolution Medicines' lead therapeutic RASONQUE (daraxonrasib), making it the first broad RAS-targeted medicine authorized for metastatic pancreatic adenocarcinoma in pretreated patients or those ineligible for multiagent chemotherapy. The approval was supported by data from the Phase 3 RASolute 302 trial. Specialty pharmacy distributor Onco360 has been mobilized for nationwide commercial distribution.
    Affected
    RVMD
    Transmission
    Commercial regulatory approval unlocks direct product revenue in oncology markets, transitioning clinical pipeline assets to commercial pharmaceutical cash flows.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    RVMDcommercial drug approval generating first-line product sales and pipeline de-riskingUp1-5dFDA approved RVMD's RASONQUE for metastatic pancreatic adenocarcinoma.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month